Transplantation and Cellular Therapy
Publisher: Elsevier · ISSN 2666-6367 · 87 articles
- Association between anti-thymocyte globulin exposure and clinical outcomes of adult undergoing haploidentical hematopoietic stem cell transplantation with myeloablative conditioning: a pharmacokinetic-guided study
- SEXUAL FUNCTION IN WOMEN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS OF AN OBSERVATIONAL STUDY
- Impact of Venetoclax Bridging on Haematopoietic Stem Cell Transplantation Outcomes in Advanced Myelodysplastic Neoplasms
- Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Infusion timing and outcomes after allogeneic hematopoietic cell transplantation across graft sources
- Risk-Adapted Donor Selection in Patients with Acute Myeloid Leukemia
- Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
- Post-transplant cyclophosphamide and single-agent tacrolimus as GvHD prophylaxis for allogeneic peripheral blood stem cell transplantation. Comparison between haploidentical and HLA matched/single-allele mismatched donors and impact of lower doses of PTCy
- Sepsis in Chimeric Antigen Receptor T-Cell Therapy: A Six-Year Nationwide Analysis of Clinical Outcomes and Healthcare Resource Utilization in Hospitalizations for Hematologic Malignancies
- Early T-cell Large Granular Lymphocyte Expansions in Patients with Cytopenias after CD19 CAR T-cell Therapy
- Reply to “Does Lower PTCy Dose Increase GVHD?”
- Association of Post-Transplant Cyclophosphamide Dose with BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplantation
- Traversing the Last Mile: Bringing Chimeric Antigen Receptor T-Cell Therapy to the Community Setting
- Thiotepa/Busulfan/Cyclophosphamide versus Busulfan/Thiotepa Conditioning For Autologous Stem Cell Transplantation in CNS Lymphoma: A Single-Center Comparative and Descriptive Experience
- Allogeneic CD33/CD123 CAR-T сells in pediatric relapsed/refractory AML: early single-center experience
- The effect of coping strategies on overall survival and other outcomes after allogeneic stem cell transplant
- Caregiver Stress and Coping during Pediatric Hematopoietic Stem Cell Transplant: Perspectives of Caregivers and Healthcare Providers
- Ligand/receptor-based chimeric antigen receptors: a promising alternative to conventional scFv designs in cancer immunotherapy
- Bone marrow niche disruption via interferon gamma-mediated CXCL9/CXCL10 secretion after allogeneic transplantation
- Attrition Factors in Patients with Metastatic Melanoma Screened for Tumor Infiltrating Lymphocyte Therapy
- Severe graft-versus-host disease and limited durable response with mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma
- When cord blood grafts may be the preferred donor choice: a position statement from the ASTCT Cord Blood Special Interest Group
- Invasive fungal infections after moderate or severe chronic graft-versus-host disease in allogeneic hematopoietic cell transplant recipients: incidence, timing, and associated factors
- Model-informed precision dosing of busulfan in Adults: Real world implications for Dosing and Transplant outcomes
- Real-world access and barriers to CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a population-based study
- Comparison of pegfilgrastim and daily G-CSF for CD34+ cell mobilization in healthy donors and post-transplant engraftment: The Pegfilgrastim-23 Study
- A multicenter study of allogeneic HSCT in Nijmegen breakage syndrome with conditioning regimen based on reduced doses of treosulfan